Teriflunomide HMR1726

DRUG5 trials

Sponsors

Sanofi

Conditions

Multiple SclerosisRelapsing Multiple SclerosisRenal Impairment

Phase 1

Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

CompletedNCT01239459

SanofiRenal Impairment

Start: 2010-11-30End: 2011-03-31Updated: 2012-03-01

A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers

CompletedNCT02046629

SanofiMultiple Sclerosis

Start: 2014-05-31End: 2014-07-31Updated: 2014-08-21

Phase 3

Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis

CompletedNCT01863888

SanofiMultiple Sclerosis

Start: 2013-10-31End: 2015-01-31Updated: 2015-03-13

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

CompletedNCT04410991

SanofiRelapsing Multiple Sclerosis

Start: 2020-06-11End: 2024-07-16Updated: 2025-07-02

Phase 4

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

CompletedNCT03856619

SanofiRelapsing Multiple Sclerosis

Start: 2019-03-27End: 2022-05-13Updated: 2023-04-19

Related Papers

Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis

New England Journal of Medicine2025-04-0830 citations

Teri-DYNAMIC: Exploring the impact of teriflunomide on immune cell population size, receptor repertoire, and function in patients with RRMS

2017-01-012 citations

TERI-DYNAMIC: Exploring the Impact of Teriflunomide on Immune Cell Population Size, Receptor Repertoire, and Function in Patients With RRMS (P5.282)

Neurology2016-04-055 citations